This SGLT2i mechanism of action is particularly interesting, as it has been well documented in animal studies, that inhibition of the TGF-Beta1/Smad3 signalling pathway significantly inhibits myocardial fibrosis and left ventricular remodelling in HF regardless of the presence of diabetes. The gene discussed is TGFB1; the disease is diabetes mellitus.